Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
Date:11/12/2008

LA JOLLA, Calif., Nov. 12 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced financial results for the third quarter ended September 30, 2008. For the three-month period, the Company posted revenue of $1.2 million and a net loss of $5.4 million. Cash and cash equivalents totaled $14.3 million at September 30, 2008.

"The past several months have been extremely productive as we further our transition to a development-only company," said Ev Graham, acting Chief Executive Officer of TorreyPines Therapeutics. "We held a successful End of Phase II meeting with the U.S. Food & Drug Administration (FDA) for tezampanel and believe we are well positioned to seek a corporate partner to continue its development. In addition, we continued to execute on our strategic plan by completing three transactions involving some of the Company's non-core assets. Looking ahead, we are on track to announce results from two clinical trials by the end of the year."

Upcoming Clinical Milestones:

-- Results from a Phase I clinical trial to evaluate the analgesic effect of NGX426, the oral prodrug of tezampanel, are on schedule to be announced in December 2008. The study is designed to evaluate the effect of NGX426 on hyperalgesia, an abnormally increased pain state, and allodynia, pain resulting from normally non-painful stimuli, when induced by intradermal injections of capsaicin.

-- Results from a Phase IIa study evaluating NGX267, a muscarinic agonist, as a potential treatment for xerostomia, are on schedule to be announced in December 2008. This study is designed to evaluate three doses of NGX267 and placebo in a four-way cross-over design in patients with xerostomia secondary to Sjogren's syndrome. The focus
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
2. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
3. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
4. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
5. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
6. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
7. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
8. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
9. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
10. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
11. TorreyPines Therapeutics Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 Research and Markets ( ... "2015 Global Survey on Flow Cytometry Adoption ... The primary goal of this research is to ... reagents. Key information the survey seeks to collect ... cytometers, predominantly used applications for flow cytometers, respondents, ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
(Date:5/20/2015)... May 20, 2015 The global genotyping ... 22.3% during the forecast period of 2015 to 2020 ... being used in drug discovery and development process and ... growth. In addition to this,heavy investments by key manufacturers ... are also propelling market growth. Browse 113 market data ...
Breaking Biology Technology:Global Survey on Flow Cytometry Adoption Trends 2015 2Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... SAN DIEGO , April 22 Neurocrine Biosciences, Inc. (Nasdaq: ... 2010 financial results after the Nasdaq market closes on Wednesday, April 28, ... discuss its financial results and provide a Company update Thursday morning, April ... Pacific Time ). , , , ...
... 22 As evidence of its drive to ... activity, Smith & Nephew ( SNN, LSE: SN) Orthopaedics ... its VERILAST technology for knee replacement implants. After simulating ... knee replacement, VERILAST technology produced an 81-percent reduction* in ...
... , April 22 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today ... 29 at 4:30 p.m. Eastern Time to discuss its financial results for ... quarter financial results after market close. , , ... , , , ...
Cached Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results 2Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 2Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 3Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 4Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 5PDL BioPharma to Announce First Quarter 2010 Financial Results and Hold Conference Call on April 29, 2010 2
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... to pre-order customers the first week of May, 2015 ... month of May. Gino Pereira ... milestone for the company as Wocket® enters the consumer ...
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... is a major obstacle for the proper treatment of patients ... of Rare Cancers was presented today by RARE CANCERS ... Oncology (ESMO) and the European Society of Pathology ... cancer patients get a timely and accurate diagnosis. The ...
... University of York scientist,s experience in seeing his partner ... him to design and synthesise new chemical agents that ... the University,s Department of Chemistry, led an international team ... the anti-coagulant heparin., Professor Smith says: ,I was sitting ...
... at the California Institute of Technology (Caltech) demonstrated a ... treatment that protected the mice from infection by a ... led by Nobel Laureate David Baltimore, have shown that ... strain of HIV found in the real world, even ...
Cached Biology News:Rare cancers: the challenge of accurate diagnosis -- press release 2From surgery to laboratory and back again 2
... NightOWL is a dedicated imaging system for ... light due to pixel size. Equipped with ... level light in animals or plants in ... circadian rhythm or Western blots. NightOWL is ...
... NovaTaq DNA Polymerase is a premium ... polymerase. This thermostable enzyme is suitable for ... ensure the highest purity and reproducible performance, ... variety of quality control assays. NovaTaq DNA ...
... The BD FACSAria cell sorter sets ... cytometry. Based on a revolutionary new ... delivers high-speed sorting and multicolor analysis. The ... sorter that incorporates a fixed-alignment cuvette flow ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Biology Products: